A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (9785-CL-0011)

Trial Profile

A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (formerly MDV3100) in Combination with Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients (9785-CL-0011)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Enzalutamide (Primary) ; Abiraterone acetate; Prednisone
  • Indications Bone metastases; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 20 Sep 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 20 Sep 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 15 Aug 2017 Planned End Date changed from 17 Sep 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top